A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001

Show full item record



Permalink

http://hdl.handle.net/10138/232079

Citation

Oronsky , B , Caroen , S , Zeman , K , Quinn , M , Brzezniak , C , Scicinski , J , Cabrales , P , Reid , T R , Trepel , J B , Abrouk , N D , Larson , C , Oronsky , A , Lybeck , H E , Day , R M & Carter , C A 2016 , ' A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001 ' , Clinical Medicine Insights: Oncology , vol. 10 , pp. 105-108 . https://doi.org/10.4137/CMO.S40429

Title: A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001
Author: Oronsky, Bryan; Caroen, Scott; Zeman, Karen; Quinn, Mary; Brzezniak, Christina; Scicinski, Jan; Cabrales, Pedro; Reid, Tony R.; Trepel, Jane B.; Abrouk, Nacer D.; Larson, Christopher; Oronsky, Arnold; Lybeck, Harry E.; Day, Regina M.; Carter, Corey A.
Contributor: University of Helsinki, Department of Physiology
Date: 2016-01-01
Language: eng
Number of pages: 4
Belongs to series: Clinical Medicine Insights: Oncology
ISSN: 1179-5549
URI: http://hdl.handle.net/10138/232079
Abstract: As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevitably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensitive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT, NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, the patient maintained a good quality of life and performance status.
Subject: 3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
cmo.s40429.pdf 889.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record